April 2026 Research Update

This month included one controlled human study suggesting that adding a short course of cerebello-spinal direct current stimulation (csDCS) to gait training can improve movement and balance more than gait training with sham stimulation. The pattern in the results was consistent across several mobility and ataxia rating measures, with the active stimulation group doing better after the treatment sessions. This is one of the few April studies that directly tested an intervention with a sham comparison in people with cerebellar ataxia. [1]

In 30 volunteers with cerebellar ataxia, five sessions of csDCS during gait training led to faster performance on a basic mobility task (Timed Up and Go), lower ataxia severity scores (SARA), and better balance scores (miniBEST) than sham stimulation. The study report described these improvements as statistically significant with large effect sizes, meaning the differences were not small within this sample. The summary did not include how long benefits lasted after the sessions, so the durability of change is not clear from this report. [1]

For patients and caregivers, this adds a clearer signal that non-drug brain and spinal stimulation paired with practice (gait training) may be able to shift short-term walking and balance measures in cerebellar ataxia, at least in a controlled research setting. Because this was a sham-controlled trial, it reduces (but does not remove) the chance that the changes were only from expectations or training alone. What remains uncertain from the provided summary is whether the effect applies equally across different genetic types of ataxia and how long improvements last after the stimulation sessions. [1]

Several human studies this month focused on finding measurable signals that track how spinocerebellar ataxia affects the body and daily function. Across these studies, different tools (MRI-based measures and nerve pathway tests) showed differences between people with SCA and controls, between SCA subtypes, or between earlier and later stages. Together, these results add to the idea that SCA is not only a cerebellar condition and that measurable changes can appear outside the cerebellum or even before clear symptoms in some groups. [2] [3] [4]

In SCA1, cervical spinal cord size on MRI was already smaller in preataxic gene carriers and continued to decline over 1 year in both preataxic and symptomatic groups compared with controls. The same report suggested that pontine (brainstem) volume changes became more prominent later, which fits a picture of different body regions showing change at different stages. For patients, this kind of work aims to identify practical measurements that could help research studies track progression more sensitively than symptoms alone. [3]

In SCA3, an MRI-derived measure used as a proxy for glymphatic system function (the brain's waste-clearance pathway) was lower than in controls in both premanifest and manifest groups, and was lowest in manifest SCA3. Lower values also lined up with longer disease duration, more disability, more brain volume loss, and broader white matter changes on diffusion imaging. This does not prove cause and effect, but it strengthens the observation that this MRI signal tends to look worse as disease burden increases in SCA3. [4]

Two studies used electrical tests and diffusion imaging to look beyond the cerebellum at major nerve pathways. One study found that people with SCA1, SCA2, and SCA3 had slowed signals along the corticospinal tract (a main movement pathway), with subtype-specific differences on diffusion imaging and correlations with disease duration in SCA3. Another study found abnormal somatosensory evoked potentials (a test of a touch-and-position pathway) in 90% of SCA3 patients but only 15% of SCA10 patients, suggesting these pathway tests may help distinguish patterns across subtypes. [2] [5]

A smaller imaging study in SCA3 linked brain chemical markers measured by MR spectroscopy to everyday function. In 23 patients, higher ratios of two cerebellar metabolic markers were correlated with higher Barthel Index scores (better activities of daily living), and exploratory modeling suggested the combined markers might help predict daily function. This adds early support for the idea that some scan-based brain chemistry measures may reflect how independent a person is day to day, but the study was small and described as preliminary. [6]

One multicenter North American analysis looked at whether education level relates to how SCA shows up. Higher education was not linked to age at onset in SCA1, SCA2, SCA3, or SCA6, but it was linked to lower disease severity at a given time point in SCA3 only. This pattern raises the possibility that life factors may relate to how severe symptoms are at assessment in SCA3, though the summary does not explain why the relationship appeared in SCA3 and not the other types. [7]

For patients, these studies mainly add measurement tools for research rather than immediate changes in day-to-day care. The clearest near-term meaning is that researchers are getting better at linking scans and pathway tests to disability level, disease stage, or subtype differences, which matters for future clinical trials that need reliable ways to track change. What remains uncertain is which of these measures will prove most reliable across hospitals and scanners, and whether any of them will predict a person's future course well enough to be used routinely. [3] [4] [2] [5] [6] [7]

This month also added early-stage research that tries to explain what is going wrong in different types of SCA and to create platforms for future treatment discovery. Across animal studies and lab work, the pattern is that multiple cell systems may be involved, including immune-like brain cells (microglia), signaling pathways in cerebellar neurons, and glutamate receptor activity. These studies do not predict what will work in people, but they help narrow down what to test next and which differences (such as sex differences) might matter. [8] [9] [10]

In an SCA2 mouse model, RNA sequencing of separated brain cell fractions showed a very large inflammatory response in microglia along with loss of neuronal transcripts within glial fractions, which the authors interpreted as consistent with severe synapse loss. The report also highlighted changes in ribosomal and splicing machinery, pointing to disrupted RNA handling as part of the disease biology in this model. For patients, this strengthens the research focus on inflammation-related pathways and RNA processing as possible contributors in SCA2, without yet showing that changing these pathways improves outcomes. [8]

In an SCA1 mouse model, long-term treatment with Ro25-6981 (a selective blocker of GluN2B-containing NMDA receptors) was reported to prevent worsening of motor activity and reduce signs of neurodegeneration, along with changes in glial reactivity and receptor subunit expression. This is an early signal that targeting specific glutamate receptor components can modify disease features in a model, while also showing that the nervous system may compensate by changing receptor subunits over time. Because this was animal work, it is a step toward hypothesis testing rather than evidence of benefit in people. [9]

A separate SCA14 mouse model focused on a PKCgamma mutation reported ataxia-like features and shifts in cerebellar signaling that were more severe in male mice, alongside analysis suggesting earlier onset in males in human data. This adds to the idea that sex differences may be biologically meaningful in at least some genetic ataxias, which could matter for how future studies are designed and interpreted. The study does not establish what should be done differently for individuals today, but it points to questions researchers can test more directly. [10]

Two human-focused exploratory studies also touched on biology beyond the brain scan level. In SCA2, blood immune profiling found subtle differences in lymphocyte subpopulations compared with controls, including higher CD20+ B cells and more HLA-DR+ cells, which may fit with the broader interest in immune involvement. In SCA1, researchers created an edited human stem cell line carrying an ATXN1 repeat expansion in one allele, which is mainly a tool to enable future lab studies of disease mechanisms and drug screening in human cells. [11] [12]

For patients and caregivers, this group of studies mainly matters for the future by sharpening what scientists think could be driving disease and by building better models to test ideas. The immune and RNA-processing findings in SCA2, the NMDA receptor targeting result in an SCA1 mouse model, and the sex-difference signals in an SCA14 model all help define more specific targets to study. What remains uncertain is which of these signals will translate into treatments that are safe and effective for people, and which findings are specific to a single SCA type or laboratory model. [8] [9] [10] [11] [12]

This month included two single-patient reports showing how unusual genetic findings can explain ataxia-like symptoms when more common testing is negative. Taken together, these cases underline that not all progressive ataxia fits the most common SCA gene panels, and that imaging patterns can sometimes point clinicians toward broader genetic evaluation. Because these are individual cases, they are best read as examples rather than proof of how often something occurs. [13] [14]

One case described a woman with progressive gait instability and a distinctive MRI finding called hypertrophic olivary degeneration, where imaging showed changes in a brainstem structure involved in movement coordination. She carried a heterozygous RNF170 mutation and tested negative for common SCA genes, leading the authors to suggest RNF170-related neurodegeneration may predispose to or mimic this imaging syndrome with prominent ataxia. The report highlights a possible genetic explanation for an otherwise unexplained imaging pattern. [13]

A second case described a Brazilian woman whose symptoms began at age 19 and who was ultimately diagnosed with SCA23 due to a pathogenic PDYN variant after an initial ataxia gene panel was negative. Brain MRI showed cerebellar atrophy, and the report noted referral to multidisciplinary rehabilitation focused on gait and swallowing difficulties. This case illustrates how broader sequencing can identify rarer SCA types and may help explain long-standing symptoms. [14]

For families, these case reports mainly add understanding about diagnosis rather than new treatment evidence. They show that a negative result on a common ataxia gene panel does not always end the search, especially when MRI or symptom patterns are unusual, and that rarer genes like RNF170 or PDYN can be involved. What remains uncertain is how frequently these genetic findings explain similar symptoms in other people, since each report describes only 1 person. [13] [14]